Dear Reader,
The largest gold buyer in the world is expected to release a revolutionary way to invest in gold in 2026.
It could change the way everyday Americans save their wealth with a click of a button.
I believe this will send this $1.60 gold stock to the stratosphere.
Think about this…
Gold would have to go up another $4,500 or so for you to double your money.
But if you buy this gold stock that is trading for around $1.60…
It just needs to go up another $1.60 for you to double your money.
That’s on the conservative side of what I believe will happen…
As soon as this revolutionary way to invest in gold is made available to the public …
Which is expected to happen in 2026.
Click here now to get the details before it’s too late…
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Written by Nathan Reiff. Posted: 1/19/2026.
In Brief
- Three biotech names with promising clinical trial data and a history of revenue generation stand out from the broader field for 2026.
- Atai Beckley and Evommune have promising pipelines focused on mental health disorders and inflammatory disease treatments, respectively.
- CorMedix has proven success with its catheter lock products and is expanding beyond the hemodialysis space in compelling ways.
Last year, the biotechnology industry leaned into artificial intelligence (AI), using machine learning to identify drug targets, optimize molecules and predict trial outcomes. Alongside the growing use of technology in drug development, companies focused on obesity, rare diseases and oncology also recorded commercial achievements.
Heading into 2026, the landscape could continue to reward investors willing to accept more risk. Lower interest rates and improved funding conditions may drive further investment in biotechs, especially those with clear paths to commercialization. Many of the standout biotech stocks to watch in 2026 have tangible catalysts that could fuel growth.
Major Mental Health Disorder Treatment Potential for Atai Beckley
Gold's getting scarce. (Ad)
Gold has weathered every financial disaster in history, and it's up more than 100 percent in the last two years. But there's another reason to pay attention now. Since 1950, roughly 70 percent of all the gold on earth has already been mined. What remains is harder to find and more costly to extract. Supplies are running out at the exact moment the world needs gold to stabilize heavily indebted financial systems. A four-stock portfolio of top gold developers is now available, selling at an average 82 percent discount to asset value.
Get the four picks plus a bonus stock with potential for significant upside.Atai Beckley (NASDAQ: ATAI) develops therapies for mental health disorders, including treatment-resistant depression (TRD) and substance use disorders. Shares of this penny stock rose about 175% over the past year, though they cooled somewhat in the final weeks of 2025. Recent investor interest has been supported by the completion of the merger between atai Life Sciences and Beckley Psytech and a redomiciliation to the United States.
Investors should watch Atai Beckley for updates on BPL-003, a nasal spray in development for TRD and alcohol use disorder that posted positive topline results in a Phase 2b trial last July and showed additional promising data in November. A Phase 3 trial is likely to begin in the second quarter of 2026. The company's sizable pipeline also includes other TRD candidates and a potential treatment for social anxiety disorder.
ATAI's clinical momentum and access to a potentially large market are encouraging, but the company must manage high R&D expenses and very modest revenue. For that reason, 2026 could be a make-or-break year. Investors willing to take a chance on a promising TRD treatment may be rewarded, but the risks remain substantial.
Hemodialysis Wins and Broadening Into New Spaces Could Drive CorMedix This Year
We've previously highlighted CorMedix Inc. (NASDAQ: CRMD) for its strength in the catheter lock market, where DefenCath has shown potential to reduce catheter-related infections and hospitalizations among dialysis patients. The company's other key asset is REZZAYO, a candidemia treatment currently in a Phase 3 trial, with data expected next quarter.
CorMedix is also expanding beyond hemodialysis, notably through its acquisition of Melinta Therapeutics, which brought fungal and bacterial infection treatments into the portfolio. The Melinta assets helped boost CorMedix's sales by roughly $13 million in September alone; investors may see additional upside when the company reports full-year results.
The firm's strong third-quarter 2025 results—with solid revenue and earnings performance—combined with a healthy cash position, should help provide a buffer as healthcare reimbursements face uncertainty in the new year. That may help explain why analysts have set a consensus price target for CRMD shares of $17.86, roughly 153% above current levels.
Big Potential in the Atopic Dermatitis Space for New Entrant Evommune
Focused on chronic inflammatory diseases, Evommune (NYSE: EVMN) is the newest biotech on our list to go public. Shares debuted via IPO in November 2025 and climbed nearly 14% during their first two months of trading. Because Evommune has less trading history than the other companies discussed, investors have less historical context, but there are reasons to expect 2026 could be a breakthrough year.
In the third quarter of 2025—the only quarterly report Evommune has released since going public—the company highlighted Phase 2 data for EVO756 and EVO301, targeting chronic inducible urticaria and certain types of atopic dermatitis (AD), respectively. Top-line results from both trials are expected in early 2026 and could serve as meaningful catalysts. Targeting atopic dermatitis may be especially important for Evommune, since AD is one of the most prevalent autoimmune conditions and many patients still lack adequate treatment options.
Evommune ended the third quarter with a modest but healthy cash position of $76 million and has begun to generate revenue from a licensing agreement in Japan, though R&D spending is likely to remain high. Analysts are optimistic about EVMN's outlook, projecting more than 84% potential upside.
This email content is a sponsored email from Golden Portfolio, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions or concerns about your account, please contact MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, S.D. 57103. United States of America..
No comments:
Post a Comment